CORZYNA
As listed in the register: CORZYNA
375 mg · tablet (extended-release)
- Prescription only
- Heart, blood pressure and circulation
- Active substance
- Ranolazine
- Made by
- Kye Pharmaceuticals Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Ranolazine). It describes the substance, not this exact product.
The mechanism of action of ranolazine’s antianginal effects has not been determined.
Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure.
Ranolazine is extensively metabolized in the gut and liver and its absorption is highly variable.
Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces.
The pharmacokinetics of ranolazine is unaffected by age, gender, or food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-19
Safety of the active substance
From the US prescribing label for the same active substance (Ranolazine). It describes the substance, not this exact product.
- Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1) ] Taking inducers of CYP3A [see Drug Interactions (7.1) ] With liver cirrhosis [see Use in Specific Populations (8.6) ] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) CYP3A inducers (e.g., rifampin, phenobarbital, St.
- John’s wort) (4, 7.1) Liver cirrhosis (4, 8.6)
Most common adverse reactions (greater than 4% and more common than with placebo) are dizziness, headache, constipation, nausea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
Spain17 matching products
- RANEXA 375 mg · comprimido de liberación prolongada5 makers
- LABIGAT 375 mg · comprimido de liberación prolongada
- RANOLAZINA ALTER 375 MG · comprimido de liberación prolongada
- RANOLAZINA AUROVITAS 375 mg · comprimido de liberación prolongada
- RANOLAZINA CINFA 375 mg · comprimido de liberación prolongada
- RANOLAZINA INTAS 375 MG · comprimido de liberación prolongada
- RANOLAZINA KRKA 375 MG · comprimido de liberación prolongada
- RANOLAZINA NORMON 375 mg · comprimido de liberación prolongada
Netherlands8 matching products
- Lazela 375 mg 375 mg · tablet met verlengde afgifte
- Ranexa 375 mg 375 mg · tablet met verlengde afgifte
- Ranogelan 375 mg tabletten met verlengde afgifte 375 mg · tablet met verlengde afgifte
- Ranolazine ELC 375 mg 375 mg · tablet met verlengde afgifte
- Ranolazine STADA 375 mg 375 mg · tablet met verlengde afgifte
- Ranolazine STADA Arzneimittel AG 375 mg 375 mg · tablet met verlengde afgifte
- Ranozek 375 mg 375 mg · tablet met verlengde afgifte
- Renofrin 375 mg 375 mg · tablet met verlengde afgifte
SwitzerlandNo exact match for this strength and form
Details
| Made by | Kye Pharmaceuticals Inc. |
|---|---|
| Active substance | Ranolazine |
| Used in | Heart, blood pressure and circulation |
| Strength | 375 mg |
| Form | tablet (extended-release) |
| Classification | C01EB18 · Heart, blood pressure and circulation |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02558947 |
| DPD drug code | 106215 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.